Gilead has had a recent major drug trial failure of a $5B

New Post Public Reply Private Reply Replies (2) Message Board
Enjay
950
Gilead has had a recent major drug trial failure of a $5B cancer drug. While reading about this problem, I also saw that they had a trial problem in 2020 with a Rheumatoid Arthritis drug estimated to have peak sales of $2B. Basis a quick search, Gilead did not pursue FDA approval of the RA drug but it is approved by the EMA. Could Gilead be on the prowl for a drug like Leronlimab?

February 2,2022

Gilead’s trouble with its $5 billion drug magrolimab is considerably worse than it disclosed in a press release last week.

Originally, the big biotech alerted investors that they had to slam the brakes on enrolling patients in a slate of clinical trials that combined the CD47 drug magrolimab with azacitidine (Vidaza). That came after the agency flagged an “apparent imbalance” in the suspected unexpected serious adverse reactions between study arms.

Then in their Q4 update Tuesday night, some small print in their presentation noted that the FDA had expanded the hold.

FDA placed partial clinical holds on trials evaluating magrolimab in combination with azacitidine as well as the fully enrolled DLBCL and MM study.

“A subsequent partial clinical hold has been placed on the Phase II multiple myeloma study and the fully enrolled Phase II DLBCL study,” explained Merdad Parsey in their Q4 call with analysts. He continued:
Importantly, patients currently enrolled in our magrolimab studies can continue treatment, and our compassionate use programs remain open. We are working with FDA to take a comprehensive look at the safety data, and we’ll share the outcome as quickly as we can. In the meantime, we remain committed to the magrolimab development program and believe that it has the potential to address an important unmet medical need in these seriously ill patients. As you know, the patients in our ENHANCE Phase III trial have a very high unmet need, with a median overall survival of only 1 to 3 years on the current standard of care.

Separate from and prior to the partial clinical hold, our Phase Ib single arm study in higher risk MDS no longer has a viable path to submission based on regulatory feedback.

Magrolimab was the jewel in the crown of Forty Seven’s pipeline, which Gilead bought out for $4.9 billion close to 2 years ago as it shifted its pipeline focus more toward oncology. In the fall of 2020, the leading anti-CD47 monoclonal antibody won breakthrough status at the FDA, burnishing Gilead’s blockbuster prospects, which had already been high after the first cut of human data.

This isn’t the first time the executive crew at Gilead have grappled with opposing views at the FDA. The agency effectively killed filgotinib for the company, wiping out a major alliance that aimed at expanding the biotech’s franchise list.

https://endpts.com/that-partial-hold-on-gilea...ally-told/



August 18,2020

In a surprise twist, the FDA has rejected Gilead’s marketing application for filgotinib, dealing a body blow to Daniel O’Day’s hopes for a rapid improvement in the big biotech’s drug portfolio with a blockbuster addition.

Late on Tuesday, Gilead $GILD put out word that the agency had turned thumbs-down on their application for rheumatoid arthritis, saying that regulators wanted to see more data from two ongoing safety studies of the drug.

Ominously, though, Gilead also noted that the “FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose.” And that could ultimately force Gilead to scrap one of the biggest development efforts in the industry.

There’s no sugarcoating the news. The best case scenario for Gilead now is a major delay as AbbVie pushes ahead with the recently approved rival Rinvoq. In calls with analysts the company outlined the agency’s frets about safety that could kill any chances of the high dose, leaving Gilead with the prospect of a weak commercial launch of a drug with limited efficacy, more similar to the aging Humira, in a packed field.

That was not supposed to happen.

Gilead had run the full suite of late-stage clinical trials — with more in the works — to prove that filgotinib lives up to its promise of being a boon to a wide range of patients. At every stage of development, the company had touted efficacy and safety data, underscoring their high expectations.

As is customary in these situations, a top-level R&D exec — in this case, CMO Merdad Parsey — expressed he was “disappointed in this outcome” and promised to carefully evaluate the response.

All the evaluating in the world, though, won’t prevent at least a major delay as Gilead waits for data from the MANTA and MANTA-RAy studies, due in H1 2021.

Still to be determined, though, was what raised a red flag about the 200 mg dose — the high dose in the Humira comparison studies and whether it would kill any chances of an OK at that dosage. That’s a common practice in the rheumatoid arthritis/anti-inflammatory field, where regulators are keenly concerned about the impact of chronic dosing intended to run for years.

Evan Seigerman at Credit Suisse picked up on the threat the CRL poses to Gilead, noting:
Gilead management cited broad concerns from the agency around the high dose, including mortality, herpes zoster infection, increased risk for malignancy, and blood-clot issues. Bottom line there is no simple fix to these complex issues, putting the entire filgotinib program (RA and beyond) at risk.

Truist analyst Robyn Karnauskas talked it over with Gilead execs and also came away with a clear impression that the franchise is at risk of being swept away.

GILD had discussions with FDA on MANTA going into NDA filing, but more talks needed on what FDA wants from MANTA and what is needed on benefit/risk profile for 200mg dose. For a competitive label, filgotinib needs better safety. We believe there is clear risk if these 2 issues aren’t resolved from a competitive standpoint. If label is not competitive, GILD may not launch if it’s not in shareholders’ best interest, which we think is smart.

Earlier in the year analysts at Cortellis, a part of Clarivate Analytics, set the consensus on peak sales for filgotinib at $1.4 billion, a top 10 drug in the pipeline. Some analysts were even more bullish, setting the top line at about $2 billion.

Gilead had carefully gathered a battery of safety data in making their pitch, drawing on a range of studies. The FDA has been acutely concerned about the JAK class of anti-inflammatories, running from restrictions on Pfizer’s JAK1/JAK3 inhibitor Xeljanz’s use to an initial rejection for Eli Lilly’s Olumiant.
Gilead signed up for a $750 million upfront to gain licensing rights to filgotinib from Galapagos, after AbbVie walked away. Then they expanded the development deal, with billions on the table, after O’Day arrived.

If the CRL does end filgo’s chances, Gilead has plenty to lean back on. Its HIV franchise remains one of the most dominant and durable in the industry. And O’Day has been wheeling and dealing on the oncology side, where he’s looking to make a splash.

Gilead’s shares slid more than 5% after the news hit, a major turn for a company with an $86 billion market cap. At Galapagos on Wednesday, it was even worse. Their shares dropped 28%.

https://endpts.com/fda-hands-gilead-a-stunnin...r-setback/


CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 22

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 92

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 26

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 11

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 57

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 239

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Laser Photonics CMS Expands Their Market Presence with New Orders

Updated Category News Views 145

Laser Photonics CMS Expands Their Market Presence with New Orders Laser Photonics Corporation (NASDAQ: LASE), a prominent global player in the manufacturing of innovative industrial laser systems, has announced recent progress from its subsidiary, Control Micro Systems (CMS). This exciting development highlights the increasing applications of laser technology in various...

Continue Reading
WuXi Biologics Expands Operations with New Syringe Production Line

Updated Category News Views 221

WuXi Biologics Expands Production Capabilities WuXi Biologics (2269.HK), a renowned global Contract Research, Development, and Manufacturing Organization (CRDMO), is set to strengthen its product capabilities by launching a new sterile filling line designed specifically for prefilled syringes (PFS). This initiative is taking place at WuXi's facility in Leverkusen,...

Continue Reading
Unlocking the Future: SEALSQ's MS6003 Secure Element Launch

Updated Category News Views 232

Revolutionizing Secure Authentication with MS6003 SEALSQ Corp (NASDAQ: LAES), a leader in semiconductor innovation, has recently announced a significant addition to its product portfolio: the MS6003 secure element chip. This state-of-the-art chip is equipped with a preloaded FIDO2 application, marking a pivotal step towards enhancing passwordless authentication in an era...

Continue Reading
Boeing's Outlook Brightens Amid Trade Deal Backlogs

Updated Category News Views 197

Boeing's Promising Trade Developments Boeing Co.'s earnings call showcased a significant shift in the global trade landscape, influenced by recent agreements during the Trump administration. This transition is likely to ease tariff pressures, providing vital support for the aerospace giant’s impressive backlog that currently exceeds $600 billion. The Financial Snapshot...

Continue Reading
Supreme Court's Decision on Appian vs. Pegasystems Verdict Case

Updated Category News Views 407

Supreme Court to Review Appian's Petition Against Pegasystems The Supreme Court of Virginia has decided to hear a significant legal case involving Appian and Pegasystems, Inc., which revolves around a staggering judgment amounting to $2.036 billion. This case is crucial as it pertains to the protection of intellectual property and trade secrets in the tech industry....

Continue Reading